Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Gail J. Roboz; Karen Yee; Amit Verma; Gautam Borthakur; Adolfo de la Fuente Burguera; Guillermo Sanz; Helai P. Mohammad; Ryan G. Kruger; Natalie O. Karpinich; Geraldine Ferron-Brady; Andre Acusta; Heather Del Buono; Therese Collingwood; Marc Ballas; Arindam Dhar; Andrew H. Wei

doi:10.1080/10428194.2021.2012667

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Gail J. Roboz, Karen Yee, Amit Verma, Gautam Borthakur, Adolfo de la Fuente Burguera, Guillermo Sanz, Helai P. Mohammad, Ryan G. Kruger, Natalie O. Karpinich, Geraldine Ferron-Brady, Andre Acusta, Heather Del Buono, Therese Collingwood, Marc Ballas, Arindam Dhar, Andrew H. Wei

Medicine

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	463-467
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	63
Issue number	2
DOIs	https://doi.org/10.1080/10428194.2021.2012667
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2021.2012667

Cite this

Roboz, G. J., Yee, K., Verma, A., Borthakur, G., de la Fuente Burguera, A., Sanz, G., Mohammad, H. P., Kruger, R. G., Karpinich, N. O., Ferron-Brady, G., Acusta, A., Del Buono, H., Collingwood, T., Ballas, M., Dhar, A., & Wei, A. H. (2022). Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia and Lymphoma, 63(2), 463-467. https://doi.org/10.1080/10428194.2021.2012667

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. / Roboz, Gail J.; Yee, Karen; Verma, Amit et al.

In: Leukemia and Lymphoma, Vol. 63, No. 2, 2022, p. 463-467.

Research output: Contribution to journal › Letter › peer-review

Roboz, GJ, Yee, K, Verma, A, Borthakur, G, de la Fuente Burguera, A, Sanz, G, Mohammad, HP, Kruger, RG, Karpinich, NO, Ferron-Brady, G, Acusta, A, Del Buono, H, Collingwood, T, Ballas, M, Dhar, A & Wei, AH 2022, 'Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes', Leukemia and Lymphoma, vol. 63, no. 2, pp. 463-467. https://doi.org/10.1080/10428194.2021.2012667

@article{c6815b9d6a9b4af99ca6935f49349094,

title = "Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes",

author = "Roboz, {Gail J.} and Karen Yee and Amit Verma and Gautam Borthakur and {de la Fuente Burguera}, Adolfo and Guillermo Sanz and Mohammad, {Helai P.} and Kruger, {Ryan G.} and Karpinich, {Natalie O.} and Geraldine Ferron-Brady and Andre Acusta and {Del Buono}, Heather and Therese Collingwood and Marc Ballas and Arindam Dhar and Wei, {Andrew H.}",

note = "Funding Information: The authors thank GlaxoSmithKline for funding the studies (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]), Bob Gagnon for his statistical analyses of the PD data and Leigh O{\textquoteright}Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, for medical writing support (funded by GSK). Funding Information: A. D., R. G. K., N. O. K., G. F-B., A. A., H. D. B., and T. C. are employees, and hold stocks/shares, in GSK. M. B. is an employee of GSK and holds stocks/shares in GSK, Celgene and Abbott. GJR participated in consultancy, advisory boards or data and safety monitoring committee for AbbVie, Actinium, Agios, Astex, Astellas, AstraZeneca, Bayer, Bluebird Bio, Blueprint Medicines, Celgene, Daiichi Sankyo, GSK, Helsinn, Janssen, Jasper Therapeutics, Jazz, Novartis, MEI Pharma, Mesoblast, Otsuka, Pfizer, Roche/Genentech, Sandoz, and Takeda. G. S. reports participation on advisory boards or data and safety monitoring committee for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Helsinn Healthcare, Hoffmann–La Roche, Janssen–Cilag, Novartis and Takeda, institutional funding and research from Celgene, Hoffman–La Roche, Janssen–Cilag and Novartis and personal fees from Abbvie, Astellas, Celgene, Janssen-Cilag and Hoffman–La Roche. K. Y. reports consulting fees or advisory role for AbbVie, Astex, Novartis, Pfizer, Celgene, Hoffman–La Roche, Otsuka, Paladin, Shattuck Labs, TaiHo and Takeda and research funding from Astex, Forma Therapeutics, Geron, Janssen, Jazz, Medimmune, Novartis, Onconova and Roche/Genentech. A. H. W. is an employee of the Walter and Eliza Hall Institute, reports research funding from Abbvie, Amgen, AstraZeneca, Celgene, Novartis, Servier and Hoffman–La Roche, honoraria and participation on advisory boards or data and safety monitoring committee for Abbvie, Amgen, Astellas, AstraZeneca, Celgene, Genentech, Janssen, MacroGenics, Novartis, Pfizer and Servier, as well as consulting fees for Servier. A. V. holds stocks/shares in Stelexis; there are no conflicts of interest with this study. G. B. participated in advisory boards or data and safety monitoring committee for Takeda and Janssen. A. F. B. reports consulting fees from AbbVie, Astellas, Celgene, Incyte, Janssen, Jazz Pharmaceutical, Mundipharma, Hoffman–La Roche and Pfizer; honoraria for educational events for AbbVie, Astellas, Celgene, Hoffman–La Roche, Incyte, Jazz Pharmaceutical, Novartis, Pfizer; participation on advisory boards or data and safety monitoring committee for Abbvie, Astellas, Celgene and Hoffman–La Roche and research funds from Novartis and Janssen. H. P. M. has nothing to declare. Funding Information: This work was supported by GlaxoSmithKline (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]). The authors thank GlaxoSmithKline for funding the studies (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]), Bob Gagnon for his statistical analyses of the PD data and Leigh O?Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, for medical writing support (funded by GSK).",

year = "2022",

doi = "10.1080/10428194.2021.2012667",

language = "English (US)",

volume = "63",

pages = "463--467",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

AU - Roboz, Gail J.

AU - Yee, Karen

AU - Verma, Amit

AU - Borthakur, Gautam

AU - de la Fuente Burguera, Adolfo

AU - Sanz, Guillermo

AU - Mohammad, Helai P.

AU - Kruger, Ryan G.

AU - Karpinich, Natalie O.

AU - Ferron-Brady, Geraldine

AU - Acusta, Andre

AU - Del Buono, Heather

AU - Collingwood, Therese

AU - Ballas, Marc

AU - Dhar, Arindam

AU - Wei, Andrew H.

N1 - Funding Information: The authors thank GlaxoSmithKline for funding the studies (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]), Bob Gagnon for his statistical analyses of the PD data and Leigh O’Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, for medical writing support (funded by GSK). Funding Information: A. D., R. G. K., N. O. K., G. F-B., A. A., H. D. B., and T. C. are employees, and hold stocks/shares, in GSK. M. B. is an employee of GSK and holds stocks/shares in GSK, Celgene and Abbott. GJR participated in consultancy, advisory boards or data and safety monitoring committee for AbbVie, Actinium, Agios, Astex, Astellas, AstraZeneca, Bayer, Bluebird Bio, Blueprint Medicines, Celgene, Daiichi Sankyo, GSK, Helsinn, Janssen, Jasper Therapeutics, Jazz, Novartis, MEI Pharma, Mesoblast, Otsuka, Pfizer, Roche/Genentech, Sandoz, and Takeda. G. S. reports participation on advisory boards or data and safety monitoring committee for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Helsinn Healthcare, Hoffmann–La Roche, Janssen–Cilag, Novartis and Takeda, institutional funding and research from Celgene, Hoffman–La Roche, Janssen–Cilag and Novartis and personal fees from Abbvie, Astellas, Celgene, Janssen-Cilag and Hoffman–La Roche. K. Y. reports consulting fees or advisory role for AbbVie, Astex, Novartis, Pfizer, Celgene, Hoffman–La Roche, Otsuka, Paladin, Shattuck Labs, TaiHo and Takeda and research funding from Astex, Forma Therapeutics, Geron, Janssen, Jazz, Medimmune, Novartis, Onconova and Roche/Genentech. A. H. W. is an employee of the Walter and Eliza Hall Institute, reports research funding from Abbvie, Amgen, AstraZeneca, Celgene, Novartis, Servier and Hoffman–La Roche, honoraria and participation on advisory boards or data and safety monitoring committee for Abbvie, Amgen, Astellas, AstraZeneca, Celgene, Genentech, Janssen, MacroGenics, Novartis, Pfizer and Servier, as well as consulting fees for Servier. A. V. holds stocks/shares in Stelexis; there are no conflicts of interest with this study. G. B. participated in advisory boards or data and safety monitoring committee for Takeda and Janssen. A. F. B. reports consulting fees from AbbVie, Astellas, Celgene, Incyte, Janssen, Jazz Pharmaceutical, Mundipharma, Hoffman–La Roche and Pfizer; honoraria for educational events for AbbVie, Astellas, Celgene, Hoffman–La Roche, Incyte, Jazz Pharmaceutical, Novartis, Pfizer; participation on advisory boards or data and safety monitoring committee for Abbvie, Astellas, Celgene and Hoffman–La Roche and research funds from Novartis and Janssen. H. P. M. has nothing to declare. Funding Information: This work was supported by GlaxoSmithKline (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]). The authors thank GlaxoSmithKline for funding the studies (GSK studies 200200 [ClinicalTrials.gov number: NCT02177812] and 205744 [ClinicalTrials.gov number: NCT02929498]), Bob Gagnon for his statistical analyses of the PD data and Leigh O?Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, for medical writing support (funded by GSK).

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85121580662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121580662&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.2012667

DO - 10.1080/10428194.2021.2012667

M3 - Letter

C2 - 34927529

AN - SCOPUS:85121580662

SN - 1042-8194

VL - 63

SP - 463

EP - 467

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this